Report

TheraCryf | FY24 results - in line; trebled shots on target

TheraCryf reported a net loss for FY24 of £3.1m together with cash and net cash of £2.0m, in line with our forecasts. Post year end, the company raised £0.8m (net) in conjunction with its acquisition of Chronos Therapeutics (Chronos), which trebled its drug development pipeline. The company has a financial runway through towards the end of FY26. Despite its advantages, TheraCryf trades on a fraction of the rating of peers with similar characteristics and has multiple prospective newsflow events due in 2024/25. We recently published an initiation on TheraCryf which sets out the full investment thesis.
Underlying
Evgen Pharma

Evgen Pharma is a clinical stage drug development company. Co.'s pipeline is based on its proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane.

Provider
Capital Access Group
Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Analysts
Colin Smith

Other Reports on these Companies
Other Reports from Capital Access Group

ResearchPool Subscriptions

Get the most out of your insights

Get in touch